CARIS LIFE SCIENCES, INC. vs CAREDX, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CAI and CDNA diverge most: on net margin, CAI reads -5.5% and CDNA reads 24.2%; on return on equity, CAI reads -8.2% and CDNA reads 26.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | CAI | CDNA |
|---|---|---|
| Price | $24.34 | $50.16 |
| Market cap | $6.9B | $2.6B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| Implied growth (priced in) | +40.4% | — |
| P/E | — | 24.2 |
| P/B | 11.64 | 6.10 |
| P/S | 7.84 | 5.66 |
| EV/EBITDA | 104.4 | 19.8 |
| Revenue growth | +79.7% | +34.3% |
| Operating margin | 10.2% | 85.8% |
| Net margin | -5.5% | 24.2% |
| Return on equity | -8.2% | 26.1% |
| Return on assets | -4.0% | 20.8% |
| Return on invested capital | 3.8% | 24.6% |
| FCF yield | 1.8% | 3.4% |
| Debt / equity | 0.66 | 0.00 |
| Current ratio | 5.53 | 4.58 |
| Altman Z (solvency) | 4.73 | 6.99 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.